Carregant...
Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients
AIM: To estimate the mean lifetime survival benefit, an essential component of health economic evaluations in oncology, of adding tumor treating fields (TTFields) to maintenance temozolomide (TMZ) for newly diagnosed glioblastoma patients. METHODS: We integrated EF-14 trial data with glioblastoma ep...
Guardat en:
| Publicat a: | CNS Oncol |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Future Medicine Ltd
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6200060/ https://ncbi.nlm.nih.gov/pubmed/30124334 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/cns-2018-0010 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|